Pfizer announces data on Ibrance's first-line treatment of HR+/HER2-metastatic breast cancer

-Pfizer recently announced that real-world evidence (RWE) published in a peer-reviewed journal proves that in female patients with HR+/HER2-metastatic breast cancer (mBC), compared with letrozole, targeting The anticancer drug Ibrance (common name: palbociclib, piperacillil) combined with first-line treatment with letrozole improved real-world progression-free survival (rwPFS) and overall survival (OS).

It is worth mentioning that this is the first large-scale comparative efficacy analysis to evaluate the therapeutic benefits of a CDK4/6 inhibitor combined with letrozole and trazole alone on progression-free survival (PFS) and overall survival (OS).

In this observational, retrospective reality analysis, at a median follow-up of approximately 2 years, after balancing baseline demographics and clinical characteristics, the median rwPFS of the Ibrance+letrozole group was 20.

The analysis also showed that the 2-year overall response rate (ORR) of the Ibrance+letrozole group and the letrozole group were 78.

Chris Boshoff, MD, Chief Development Officer of Oncology, Pfizer Global Product Development, said: "Real-world evidence has been incorporated into how we innovate and advance breast cancer patient care.

Angela DeMichele, MD, Professor of Breast Cancer Excellence and Principal Investigator at the Perelman School of Medicine at the University of Pennsylvania, said: “Real-world evidence is increasingly being used to supplement traditional randomized clinical trial data in order to better understand a The effectiveness of the therapy in routine clinical practice and provides information for treatment decisions.

The data for this retrospective observation and analysis was collected from the Flatiron Health de-identified longitudinal database, which includes patient records from more than 280 community cancer clinics from the Flatiron network, as well as partnerships with major academic cancer centers across the United States.

The data of this reality analysis is consistent with the available data of the PALOMA-2 Phase 3 trial, which evaluated Ibrance + letrozole and placebo + letrozole as the initial endocrine therapy for HR+/HER2-mBC postmenopausal women.

Ibrance is a first oral targeted CDK4/6 inhibitor that can selectively inhibit cyclin-dependent kinase 4 and 6 (CDK4/6), restore cell cycle control, and block tumor cell proliferation.

Ibrance is the world's first CDK4/6 inhibitor.

In 2020, Ibrance's global sales reached 5.

Original source: Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer